An investor’s guide to vaccines: inoculation set to be next pot of gold
What is at stake in this booming trade and who stands to benefit?
When investors try to identify the next exciting frontier for mankind, they may think of conquering outer space. But there’s a more vital one here on Earth.
The vaccine industry and the vast ecosystem surrounding it had areas of rapid growth before the pandemic, with developments such as the approval of a new shingles vaccine by the US Food and Drug Administration (FDA).
But the sector has exploded as companies race to develop Covid-19 vaccinations, treatments, booster shots and more. Some 299 vaccine candidates are listed on the World Health Organisation’s (WHO) Covid-19 vaccine tracker, with 114 in some phase of clinical development and the other 185 in earlier stages. Emerging technologies such as the use of messenger RNA (mRNA) as a delivery system hold the potential to speed up the development of vaccines to combat other infectious diseases, as well as for personalised cancer treatments...